Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and be applied to a wide range of solid tumour types.
In 2009, Oncimmune launched its proprietary platform technology for early cancer detection, called EarlyCDT®. The first test, EarlyCDT®-Lung, was commercialised in 2009 and test marketed until 2012, at which time it launched nationally across the US and since over 150,000 commercial tests have been sold. It is now available through physicians in the US and also privately in the UK and other regions.
EarlyCDT®-Lung is a simple blood test which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy.
Oncimmune Ltd is headquartered in Nottingham, UK and testing is conducted in our CLIA-approved laboratory, based in Kansas City, USA.
In 2009, Oncimmune launched its proprietary platform technology for early cancer detection, called EarlyCDT®. The first test, EarlyCDT®-Lung, was commercialised in 2009 and test marketed until 2012, at which time it launched nationally across the US and since over 150,000 commercial tests have been sold. It is now available through physicians in the US and also privately in the UK and other regions.
EarlyCDT®-Lung is a simple blood test which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy.
Oncimmune Ltd is headquartered in Nottingham, UK and testing is conducted in our CLIA-approved laboratory, based in Kansas City, USA.
Location: Germany, North Rhine-Westphalia, Dortmund
Employees: 51-200
Phone: +44 115 823 1869
Total raised: $6.7M
Founded date: 2006
Investors 3
| Date | Name | Website |
| - | BioCity | biocity.co... |
| 13.03.2022 | IPF Partne... | ipfpartner... |
| - | Balderton ... | balderton.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.09.2017 | - | $6.7M | - |
Mentions in press and media 4
| Date | Title | Description |
| 02.11.2021 | Annual results 2021 | 2 November 2021 Oncimmune Holdings plc ("Oncimmune", the "Company" and, together with its subsidiaries, the "Group") Full year results and progress update FY2021 revenues of £3.7 million (over 6x increase on FY... |
| 30.06.2019 | Biodesix to buy U.S. lab, lung nodule test from Oncimmune | A U.S.-based diagnostics company is expanding its presence in lung cancer with the acquisition of assets from a firm based in the U.K. Boulder, Colorado-based Biodesix said Friday that it would buy Nottingham, U.K.-based Oncimmune’s U.S. op... |
| 28.06.2019 | Biodesix extends its blood-based lung cancer diagnostic portfolio | Boulder-based Biodesix, Inc. is acquiring a Kansas lab run by Oncimmune Holdings, a global immunodiagnostics group, and is partnering with it to help commercialize its lung nodule malignancy risk test in the United States as part of an agre... |
| - | Biodesix to buy U.S. lab, lung nodule test from Oncimmune | A U.S.-based diagnostics company is expanding its presence in lung cancer with the acquisition of assets from a firm based in the U.K. Boulder, Colorado-based Biodesix said Friday that it would buy Nottingham, U.K.-based Oncimmune’s U.S. op... |